Visual and Optical Coherence Tomography Outcomes of Intravitreal Bevacizumab and Ranibizumab in Inflammatory Choroidal Neovascularization Secondary to Punctate Inner Choroidopathy

Cornish, Kurt Spiteri; Williams, G.; Gavin, Michael P.; Imrie, Fraser

doi:10.5301/ejo.2010.6117

Cited by 33 publications

(15 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In addition, Kramer et al reported that in patients with choroidal neovascularization related to inflammatory diseases, intravitreal injections of bevacizumab on an as-needed basis resolved leakage and subretinal fluid and improved visal acuity [27]. Several recent studies have reported that anti-VEGF agents, bevacizumab and ranibizumab were efficacious in treating CNV secondary to PIC [8, 28, 29]. Particularly, a case series study found that intravitreal anti-VEGF resolved CNV secondary to PIC over a 3–28 months follow-up period [10].…”

Section: Discussionmentioning

confidence: 99%

“…In a retrospective case series, Mansour et al [29] found that intravitreal injection of bevacizumab improved BCVA by 2.2 lines on average in treated PIC eyes with CNV. Cornish et al [8] showed that BCVA of 11.1% treated eyes deteriorated one year after intravitreal bevacizumab or ranibizumab injection. In our study, no treated eyes showed a decrease in BCVA; however, because of the differences in study designs and other factors, the studies are not directly comparable.…”

Section: Discussionmentioning

confidence: 99%

“…The first-line treatment of CNV is intravitreal injections of anti-VEGF agents administered on an as-needed basis. Currently available anti-VEGF agents include ranibizumab, bevacizumab and aflibercept [8–16]. …”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Peng

Zhang

et al. 2017

BMC Ophthalmol

View full text Add to dashboard Cite

BackgroundTo evaluate the efficacy and safety of intravitreal conbercept (KH902) as the primary treatment of choroidal neovascularization secondary to punctate inner choroidopathy.MethodsThis study was a retrospective, consecutive, observational case series. We reviewed medical records of 16 eyes (16 patients) with naive subfoveal or juxtafoveal choroidal neovascularization secondary to punctuate inner choroidopathy that were treated with intravitreal conbercept injections. All patients completed at least six months of follow-up. Best-corrected visual acuity (BCVA) was measured, and anatomical features were assessed with fluorescein angiography, indocyanine green angiography, and optical coherence tomography.ResultsAt the month-6 follow-up visit, best-corrected visual acuity improved from 0.70 ± 0.36 (with approximate Snellen equivalent of 20/100) to 0.44 ± 0.25 (20/50 in Snellen) logarithm of the minimum angle of resolution (logMAR) (P = 0.003). Mean improvement of vision was 2.6 lines, with 50% treated eyes (8 eyes of 16) showing an improvement of ≥3 lines and 62.5% (10 eyes of 16), obtaining an improvement of ≥2 lines; all 16 eyes had stable or improved vision. Mean central retinal thickness decreased from 294.94 ± 102.68 μm to 206.56 ± 61.71 μm (P = 0.005). Fifteen eyes (93.75%) showed absence of CNV leakage at the end of the study period. No conbercrept-related systemic or ocular adverse events were observed.ConclusionIntravitreal injection of conbercept significantly improved visual and anatomical outcomes in choroidal neovascularization secondary to punctate inner choroidopathy over a 6-month follow-up period.Trial registration ISRCTN85678307, retrospectively registered on May 11, 2017.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Peng

Zhang

et al. 2017

BMC Ophthalmol

View full text Add to dashboard Cite

show abstract

“…In most of these studies local or systemic steroid therapy was associated, and in two of them [25, 31] immunosuppressive drug was used in the majority of patients. Subsequently in the following years, the use of anti-VEGF therapy increased and IVB became available; 12 case series and 2 comparative retrospective studies about the IVB treatment in uveitis-related CNV are reported (Lott et al [38] and Cornish et al [45]). The first compares PDT to IVB in MC and the second IVB to IVR in PIC, but only in few cases.…”

Section: Therapy and Clinical Studiesmentioning

confidence: 99%

Management of Uveitis-Related Choroidal Neovascularization: From the Pathogenesis to the Therapy

D'Ambrosio

Tortorella

Iannetti

2014

Journal of Ophthalmology

View full text Add to dashboard Cite

Inflammatory choroidal neovascularization is a severe but uncommon complication of uveitis, more frequent in posterior uveitis such as punctate inner choroidopathy, multifocal choroiditis, serpiginous choroiditis, and Vogt-Koyanagi-Harada syndrome. Its pathogenesis is supposed to be similar to the wet age related macular degeneration: hypoxia, release of vascular endothelial growth factor, stromal cell derived factor 1-alpha, and other mediators seem to be involved in the uveitis-related choroidal neovascularization. A review on the factors implicated so far in the pathogenesis of inflammatory choroidal neovascularization was performed. Also we reported the success rate of single studies concerning the therapies of choroidal neovascularization secondary to uveitis during the last decade: photodynamic therapy, intravitreal bevacizumab, and intravitreal ranibizumab, besides steroidal and immunosuppressive therapy. Hereby a standardization of the therapeutic approach is proposed.

show abstract

“…Both have come into increasing use as intravitreal agents in the treatment of choroidal neovascular membranes (CNVM) secondary to numerous etiologies, including exudative AMD, myopia, punctate inner choroidopathy, Best's vitelliform dystrophy, angioid streaks, and idiopathic CNVM, among others. [1][2][3][4][5] Sorsby macular dystrophy is characterized by bilateral CNVM typically associated with midperipheral drusen and presenting in the fourth to fifth decade of life, and associated with mutations in the tissue inhibitor of the metalloproteinase-3 (TIMP 3) gene. 6,7 Argon laser has proven ineffective for the juxtafoveal or extrafoveal CNVM.…”

Section: Introductionmentioning

confidence: 99%

Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Choroidal Neovascularization Due to Sorsby Macular Dystrophy

Kapoor

Bakri

2013

Journal of Ocular Pharmacology and Therapeutics

View full text Add to dashboard Cite

Purpose: To report the first case of intravitreal bevacizumab and ranibizumab to treat choroidal neovascularization secondary to Sorsby macular dystrophy. Case: A 57-year-old male with metamorphopsia, color vision deficits, and ocular family history of Sorsby macular dystrophy was found to have a choroidal neovascular membrane (CNVM) in his left eye. He was initially treated with intravitreal bevacizumab and had visual acuity improvement and resolution of the subretinal fluid on OCT. After 8 injections, he developed presumed mild inflammation secondary to intravitreal bevacizumab and was switched to combination intravitreal bevacizumab/dexamethasone in his left eye, which consistently demonstrated efficacy in stabilizing his vision and the CNVM without producing intraocular inflammation. The right eye later developed the CNVM and he was started on intravitreal bevacizumab in this eye as well. After 8 injections in the right eye, he experienced a similar inflammatory reaction following intravitreal bevacizumab injections and was switched to combination intravitreal bevacizumab/dexamethasone in the right eye as well. Subsequently, he was switched to intravitreal ranibizumab in the left eye alone, which continued to stabilize his vision and OCT and did not cause an inflammatory reaction as he previously experienced with bevacizumab. After 5 ranibizumab injections, he experienced no inflammatory response that he appeared to have with bevacizumab, but chose to switch back to combination intravitreal bevacizumab and dexamethasone due to financial reasons. Initially, in his clinical course, he experienced consistent visual acuity improvements with intravitreal antivascular endothelial growth factor therapy and continues to enjoy functional vision nearly 7 years after his initial symptoms. Conclusions: Intravitreal bevacizumab and ranibizumab demonstrated efficacy in this case in the treatment of CNVM associated with Sorsby macular dystrophy.

show abstract

Visual and Optical Coherence Tomography Outcomes of Intravitreal Bevacizumab and Ranibizumab in Inflammatory Choroidal Neovascularization Secondary to Punctate Inner Choroidopathy

Abstract: Over a 1-year period, bevacizumab and ranibizumab can be safely and successfully used to treat inflammatory CNV secondary to PIC, avoiding the need for systemic immunosuppression in the majority of patients.

Cited by 33 publications

References 17 publications

Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Efficacy and safety of conbercept as a primary treatment for choroidal neovascularization secondary to punctate inner choroidopathy

Management of Uveitis-Related Choroidal Neovascularization: From the Pathogenesis to the Therapy

Intravitreal Anti-Vascular Endothelial Growth Factor Therapy for Choroidal Neovascularization Due to Sorsby Macular Dystrophy

Contact Info

Product

Resources

About